Open surgical approach to management of rhino-orbito-cerebral mucormycosis
DOI:
https://doi.org/10.18203/issn.2454-5929.ijohns20214902Keywords:
Mucormycosis, Rhino-orbito-cerebral mucormycosis, Open surgical approach, Surgical debridementAbstract
Background: Since December 2019, when novel corona virus (COVID 19) was reported, it has spread widely to cause a pandemic. Rhino-orbito-cerebral Mucormycosis (ROCM), an opportunistic fungal infection caused by the order Mucorales and class Zygomycetes has led to an epidemic in our country.
Methods: This prospective cross sectional study was conducted at a 1200 bed tertiary care teaching hospital in Mysore. All patients of ROCM who presented to us for treatment were selected for the study after informed consent. Only those patients who were operated via open approach were included.
Results: Median age of the patients was 50 years (SD±10). 49 were male patients (67.1%). Diabetes mellitus was the most common underlying co-morbidity seen in 71 patients (97.3%). Facial pain (100%) and facial swelling (90.4%) were the most common presenting complaint. KOH positivity from nasal swab for Mucormycosis was positive in only 37 patients (50.7%). Traditional inaccessible areas to endoscope like the premaxilla, lateral orbit cavity, infra temporal fossa and hard palate were tackled by the open surgical approach route. Advantages of open surgical approach being the access to areas which are traditionally difficult to approach via the endoscope, aggressive debridement is possible which might be challenging endoscopically. Complications like wound dehiscence, oro-antral fistula, osteomyelitis and abscess were noted in our study.
Conclusions: Open surgical approach offers a very viable, affordable and a very effective means for aggressive surgical debridement of infection and reduce mortality associated with ROCM.
References
Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556-69.
Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Canti¬nieaux B, Verdonck A et al. Mucormycosis during deferoxamine therapy is a sidero¬phore-mediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993;91:1979-86.
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL et al. Epidemiology and out¬come of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-53.
Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Per¬fect JR, Chin-Hong PV et al. Risk factors for mortality in patients with mucormycosis. Med Mycol. 2012;50:611-8.
Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Her¬moso D, Huerre M et al. French Mycosis Study Group. A global analysis of mucor¬mycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis. 2012;54(1):S35-43.
Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K et al. European Con¬federation of Medical Mycology Working Group on Zygo¬mycosis. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomy¬cosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859-67.
Cinque P, Bossolasco S, Vago L, Fornara C, Lipari S, Racca S et al. Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection? Clin Infect Dis. 1997;25:634-9.
Elinav H, Zimhony O, Cohen MJ, Marcovich AL, Benenson S. Rhinocerebral mucormycosis in patients without predisposing medical conditions: a review of the literature. Clin Microbiol Infect. 2009;15:693-7.
Goldstein EJ, Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48:1743-51.
Danion F, Aguilar C, Catherinot E, Alanio A, DeWolf S, Lortholary O et al. Mucormycosis: New Developments into a Persistently Devastating Infection. Semin Respir Crit Care Med. 2015;36:692-705.
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303-10.
Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B et al. Mucormycosis ECMM MSG Global GuidelineWriting Group; et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperationwith theMycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:e405-21.
Kolekar JS. Rhinocerebral Mucormycosis: A Retrospective Study. Indian J Otolaryngol Head Neck Surg. 2015;67(1):93-6.
Kasapoglu F, Coskun H, Ozmen OA, Akalin H, Ener B. Acute invasive fungal rhinosinusitis: evaluation of 26 patients treated with endonasal or open surgical procedures. Otolaryngol Head Neck Surg. 2010;143(5):614-20.
